Target Name: ETS2
NCBI ID: G2114
Review Report on ETS2 Target / Biomarker Content of Review Report on ETS2 Target / Biomarker
ETS2
Other Name(s): ETS proto-oncogene 2, transcription factor, transcript variant 2 | Protein C-ets-2 isoform 2 | V-ets avian erythroblastosis virus E26 oncogene homolog 2 | Protein C-ets-2 (isoform 1) | ETS proto-oncogene 2, transcription factor | ETS2_HUMAN | v-ets avian erythroblastosis virus E26 oncogene homolog 2 | V-ets avian erythroblastosis virus E2 oncogene homolog 2 | ETS2IT1 | v-ets erythroblastosis virus E26 oncogene homolog 2 | OTTHUMP00000115976 | ETS proto-oncogene 2, transcription factor, transcript variant 1 | ETS2 variant 1 | Oncogene ETS-2 | ETS2 variant 2 | oncogene ETS-2 | Protein C-ets-2 | OTTHUMP00000115973 | v-ets avian erythroblastosis virus E2 oncogene homolog 2 | OTTHUMP00000115974 | V-ets erythroblastosis virus E26 oncogene homolog 2

ETS2: A Potential Drug Target and Biomarker for Many Diseases

ETS2, or ETS proto-oncogene 2, is a transcription factor that plays a crucial role in the regulation of cell growth, differentiation, and survival. It is a key regulator of the hematopoietic stem cell (HSC) and has been implicated in the development and progression of many diseases, including leukemia, myelodysplastic syndromes, and myopathies.

ETS2 is a protein that is expressed in a wide range of tissues and cells, including the blood cells, tissues, and organs. It is a key transcription factor that regulates the expression of many target genes, and it has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

One of the most promising aspects of ETS2 is its potential as a drug target. Several studies have shown that inhibiting the activity of ETS2 has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, ETS2 is also a promising biomarker for several diseases. The expression of ETS2 has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that ETS2 may be a useful biomarker for these diseases and could potentially be used in the development of new diagnostic tests and therapies.

Another promising aspect of ETS2 is its role in the regulation of hematopoietic stem cell (HSC) biology. ETS2 has been shown to play a key role in the regulation of HSC stem cell self-renewal and proliferation, as well as the development of mature blood cells. This suggests that ETS2 may be a potential drug target for the treatment of HSC-related diseases, such as leukemia and myelodysplastic syndromes.

In conclusion, ETS2 is a transcription factor that has been shown to play a crucial role in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker make it an attractive target for the development of new therapies for a wide range of diseases. Further research is needed to fully understand the role of ETS2 in these diseases and to develop effective treatments.

Protein Name: ETS Proto-oncogene 2, Transcription Factor

Functions: Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription

The "ETS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ETS2-AS1 | ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7